QurAlis
PrivateLast Round
Series B
Extension
Aug 21, 2025
Total Funding Raised
$161.25M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
QurAlis operates in Healthcare & Life Sciences and is based in Cambridge, Massachusetts. Its latest recorded funding round was a Series B Extension round in August 2025.
QurAlis is a biotechnology company that develops precision therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases using genetically validated targets.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Precision Medicine, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting
AI Layer
Infrastructure
Historical Pricing
Historical view of private secondary pricing and transaction trends.
QurAlis Comparables
Compare QurAlis with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| AcuraStem | 84% | |
| Prilenia Therapeutics | 84% | |
| Alector | 77% |
For institutional investors. Book with your work email.
QurAlis Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B Extension | Aug 21, 2025 | ||||
| Series B | Mar 9, 2023 | ||||
| Series A | May 13, 2020 | ||||
| Seed | Nov 19, 2018 | ||||
| Seed | Apr 5, 2018 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
QurAlis Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| The ALS Association | Grant |
| EQT Life Sciences | Series B |
| Dolby Family Ventures | Series A, Series B |
| MP Healthcare Venture Management | Series A, Seed, Series B |
| Mitsui Global Investment | Series A, Series B |
| Acks | Seed |
| Droia Ventures | Series A, Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors increased 56% MoM, from 3.2K to 5K.
- Dec 2, 2025
Presenting Phase 1 data for QRL-101, a selective Kv7.2/7.3 ion channel opener.
For institutional investors. Book with your work email.
QurAlis Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about QurAlis's valuation, stock price, and market status.
Is QurAlis a public or private company?
QurAlis is a private company.
What is the current stock price of QurAlis?
QurAlis is a private company, so its shares have no public market price. Caplight tracks QurAlis's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is QurAlis worth (valuation)?
Valuation information for QurAlis is not publicly available.
Can I buy QurAlis stock?
QurAlis shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was QurAlis's last funding round?
QurAlis's most recent funding round was Series B Extension on August 21, 2025.
Who are the main investors in QurAlis?
Key investors in QurAlis include EQT Life Sciences, Acks, Droia Ventures, BioInnovation Capital, Viva BioInnovator.
Will QurAlis IPO soon?
No public IPO plans have been announced for QurAlis.
How can I track QurAlis secondary market activity?
Caplight tracks bids, offers, and trades in QurAlis's shares on secondary markets.